Loading stock data…
MRNA
$47.50-0.10 (-0.21%)
Market OpenUpdated 3:47 PM EDT
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Moderna, Inc. in the Healthcare sector is trading at $47.50 with a market capitalization of $18.7B. Wall Street consensus targets $43.20 (20 analysts), implying a -9.1% move over the next 12 months. The stock is currently 20% below its 52-week high of $59.55, remaining 24.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -9.1% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$47.50
Potential Downside
0%
Whystock Fair Value$47.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Hold
Mean target$43.20-9.1%
Range$21.00 – $69.00
Fundamentals
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pand...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$18.72B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.12%
Volume
Today's trading volume
3.98M
Recent News
Does Moderna Need to Start Making Money?
Moderna Is Losing Billions. Here's Why That Might Be Exactly the Right Strategy.
3 ETFs For the Coming Genomics Revolution
Genomics companies are an exciting frontier in health care, and ETFs can help to diversify to control risk while positioning investors to benefit.
How Investors May Respond To Moderna (MRNA) mRNA Advances in Personalized Cancer and Emerging Infectious Diseases
In recent days, Moderna and Merck reported five-year Phase 2b data showing that their personalized mRNA melanoma vaccine intismeran autogene, combined with Keytruda, substantially reduced the risk of cancer recurrence, metastasis, and death compared with Keytruda alone. At the same time, Moderna secured up to US$50.00 million in funding from CEPI for its Bundibugyo ebolavirus mRNA vaccine candidate, underscoring how its platform is being applied to both oncology and emerging infectious...
Is Merck & Co. (MRK) One of the Best Cheap Stocks to Buy for Beginners?
Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. Moderna, Inc. and Merck & Co., Inc. (NYSE:MRK) announced on June 1 detailed results from a planned five-year follow-up analysis of the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study evaluating intismeran autogene in combination with KEYTRUDA® in patients with high-risk melanoma following […]
Novavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue?
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.